Somapacitan (Sogroya)

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 13 September 2026

Somapacitan is a real, FDA-approved once-weekly growth hormone that solves the same how-do-you-make-hGH-last-a-week problem as lonapegsomatropin with a completely different chemical trick — reversible albumin binding instead of a prodrug — and it now covers both adults and four separate pediatric growth-disorder indications.

In brief

Should you care? Relevant alongside lonapegsomatropin if you're comparing once-weekly growth hormone options — same clinical goal, genuinely different molecular approach, covered here as this site's second once-weekly hGH page.

The short version

Reversible albumin binding, not a prodrug: a small chemical tag lets the intact hormone bind and release from the body's own albumin, extending its half-life.
Approved for adults first (2020), then expanded across four separate pediatric indications by 2026.
A large, placebo-controlled adult trial (REAL 1) and an active-controlled pediatric trial (REAL4) both back its approvals.

A different once-weekly trick than lonapegsomatropin

Somapacitan (Sogroya, Novo Nordisk) is recombinant human growth hormone modified with a small (about 1,200 Da) albumin-binding moiety attached to the hormone itself. Rather than being released from an inert carrier the way lonapegsomatropin is, the intact somapacitan molecule reversibly binds circulating albumin — the most abundant protein in blood plasma — which slows its clearance and lets a single injection remain active for about a week. It is the same underlying hormone as daily somatropin products, delivered through a molecular engineering trick rather than a chemical change to its growth-promoting activity.

REAL 1: the adult trial

The FDA approved somapacitan on 28 August 2020 for adults with growth hormone deficiency, based on the Phase 3 REAL 1 trial (Johannsson G, et al., J Clin Endocrinol Metab 2020;105(4):e1358-e1376, PMID 32022863, DOI 10.1210/clinem/dgaa049) — a placebo-controlled and active-controlled (open-label) trial across clinics in 17 countries that randomized 301 treatment-naive adults with GH deficiency to once-weekly somapacitan, daily GH, or placebo for 34 weeks. The trial demonstrated somapacitan's efficacy against placebo, with a safety profile comparable to daily GH and no new safety signals identified.

Expanding into four pediatric indications

The FDA first approved somapacitan for pediatric growth hormone deficiency in children 2.5 years and older in April 2023, based on the Phase 3 REAL4 trial, which found once-weekly somapacitan's annualized height velocity (11.2 cm/year) comparable to daily somatropin (11.7 cm/year). On 27 February 2026, the FDA expanded somapacitan's pediatric approval to three additional indications: idiopathic short stature, short stature in children born small for gestational age with no catch-up growth by age 2, and growth failure associated with Noonan syndrome — making somapacitan, as of this review, the only once-weekly growth hormone product covering that many separate pediatric growth-disorder indications alongside its adult approval.

Current status

Somapacitan is actively marketed by Novo Nordisk as Sogroya, available as a multi-dose pen in 5mg, 10mg, and 15mg strengths. As with any approved hGH product, its trial evidence applies to diagnosed deficiency and growth-disorder states specifically — see this site's Human Growth Hormone page for why that evidence doesn't extend to off-label anti-aging or bodybuilding use in someone who isn't GH-deficient.

References

Johannsson G, Gordon MB, Højby Rasmussen M, et al., "Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial," J Clin Endocrinol Metab 2020;105(4):e1358-e1376, PMID 32022863, DOI: 10.1210/clinem/dgaa049.
FDA approval of Sogroya (somapacitan-beco) for adult growth hormone deficiency, 28 August 2020; FDA approval for pediatric growth hormone deficiency (age 2.5+), April 2023, based on the Phase 3 REAL4 trial; FDA approval of three additional pediatric indications (idiopathic short stature, small-for-gestational-age short stature, Noonan syndrome growth failure), 27 February 2026 (Novo Nordisk press releases and FDA approval records).